Castor Pitch Deck: Slide-by-Slide Breakdown

The 9-Slide Series B Strategy

Castor’s Series B deck is an exercise in restraint. Raising $45M usually involves a 20-slide deep dive into unit economics, cohort analysis, and multi-year projections. Instead, Castor relies on the sheer weight of their existing footprint. By 2021, the company wasn't just a startup; it was a critical piece of global health infrastructure. This deck is designed to prove that the 'experiment' phase is over and the 'scaling' phase is in full swing.

Slide 1: Title and Vision

The cover slide introduces the company name and the primary value proposition: Making Decentralized Trials Scale . It features the name of the founder, Derk Arts, MD, PhD, which immediately establishes clinical and academic credibility. The date is July 2021, and the slide is marked as strictly confidential. The imagery depicts a connected ecosystem: a patient at home, a researcher in a lab, and a central cloud server, visually explaining the 'decentralized' concept without words.

Slide 2: The Global Footprint

This is the 'Credibility Slide.' Castor does not wait until the end to show their pedigree. They list offices in Amsterdam and New Jersey and a team of 100+. Crucially, they disclose their funding history: $60m total including the 2018 Seed, 2020 Series A, and 2021 Series B. The slide features logos for F-Prime, Eight Roads, and Two Sigma Ventures. The 'Successful Track Record' section is the highlight, citing 7,500+ supported studies , 2,600,000 enrolled patients , and 250,000,000+ data points . This scale is intended to make the investment feel low-risk.

Slide 3: The Industry Crisis

Slide 3 frames the problem. The headline states, Clinical research is stuck in the 1980s . It uses eight data blocks to quantify the pain: 7.5 years to take a drug to market, a 130% increase in R&D costs over the last 8 years, and the fact that 80% of non-Covid studies were delayed due to the pandemic. The most damning stat is that clinical trial automation has only achieved 8% of its potential versus a 42% target. This slide justifies why a new platform is a necessity, not a luxury.

Slide 4: The DCT Opportunity

This slide transitions from the problem to the market solution. It defines Decentralized Clinical Trials (DCT) and claims the market is growing from $2.5Bn to $10Bn . It lists benefits for two stakeholders: patients (less travel, increased access) and commercial research (50-65% increased recruitment rates, 40% higher retention). By citing a 25% reduced cost to develop new assets, Castor pitches itself as a margin-expansion tool for big pharma.

Slide 5: The Unified Platform

Slide 5 focuses on the product. It shows a 'unified platform' across mobile, tablet, and desktop, covering Enrollment, eConsent, Capture, and Management. The slide lists four specific efficiency gains: 60% shorter time to first patient , 30% less time spent on data cleaning , 99% self-service , and 70% time saved with EHR imports . The inclusion of compliance logos (HIPAA, GDPR, FDA 21 CFR Part 11) at the bottom addresses the primary barrier to entry in healthtech: security and regulation.

Slide 6: The WHO Solidarity Trial

This is the deck's 'mic drop' moment. Castor highlights its role in the World Health Organization (WHO) Solidarity Trial . They provide metrics for this specific project: ~1.5m data points, 3,000 investigators, 15,000+ patients, and 30 countries. They even include a screenshot of a New England Journal of Medicine article. For a Series B investor, this proves the platform can handle the highest possible stakes in global medicine.

Slide 7: The Future Roadmap

Slide 7 provides a historical timeline of clinical research, starting from 200 BC to a projected 2035. Castor positions itself at the '2010-2020' mark of 'Connected Trials' and looks toward Computational Trials in 2035. The text mentions that their vision goes beyond SaaS, aiming to dominate the future through 'machine readable data and AI.' This slide is meant to show that while they are winning today, their ultimate ceiling is much higher.

Slide 8: Press and Context

The final content slide provides links to recent press releases and background reading from investors like Two Sigma and Bessemer. This serves as a 'further reading' list for analysts performing due diligence, reinforcing the narrative that the industry is moving toward a 'virtual world.'

Slide 9: Appendix/Call to Action

The final slide is a promotional graphic for the platform hosting the deck, not part of the original Castor presentation. The original deck effectively ends on the press links.

What Castor Does Well

Massive Social Proof: Leading with the WHO Solidarity Trial is a brilliant move. In enterprise software, especially in life sciences, the biggest fear is 'will this work at scale?' Castor answers this by showing they are already powering one of the most important global trials in history.

Metric-Driven Value: Every slide contains hard numbers. Whether it is the 250 million data points or the 60% reduction in time to first patient, the deck avoids vague marketing speak in favor of quantifiable outcomes.

Regulatory Reassurance: By placing compliance certifications (ISO27001, GDPR, HIPAA) on multiple slides, they proactively answer the first ten questions any institutional investor would ask about data privacy.

What is Missing from the Deck

No Team Slide: While the founder is mentioned on the cover, there is no slide detailing the executive team, their backgrounds, or the board of directors. For a Series B, investors usually want to see the 'bench strength' behind the founder.

No Financials: The deck is entirely silent on revenue, ARR growth, burn rate, or customer acquisition costs (CAC). While these were likely in a separate data room, their absence in the pitch deck makes it a 'vision and validation' deck rather than a 'business model' deck.

No Competitive Landscape: The deck mentions that the industry is 'stuck in the 1980s,' but it doesn't name or compare Castor to other modern DCT players like Medable or Science 37. It assumes the investor already knows the competitive set.

No Use of Funds: There is no 'The Ask' slide. It is unclear how the $45M will be spent—whether on R&D, international sales expansion, or acquisitions.

Founder's Playbook: What to Copy

The 'Credibility First' Approach: If you have a massive, recognizable customer or a staggering data metric, do not hide it on slide 12. Castor puts their best numbers on Slide 2. This sets a tone of authority for the rest of the presentation.

Visualizing the 'Old Way' vs. 'New Way': Slide 3 and 4 do a great job of contrasting the 1980s-style paper trials with the modern, decentralized approach. Using icons and clear percentages makes the 'opportunity' feel inevitable rather than speculative.

Focus on Stakeholder Benefits: Castor doesn't just say the software is good; they explain why it's good for the patient (less travel) and the sponsor (25% reduced cost). Always map your features to the specific financial or emotional benefits of the person paying the bill.

Conclusion: Castor’s deck is a high-signal, low-noise presentation. It operates on the assumption that the Series B investor is already sold on the category (DCT) and only needs to be convinced that Castor is the most proven, compliant, and scalable player in that category. By leaning on the WHO partnership and their 250 million data points, they make that case successfully.